Summary of Vir Biotechnology's Q2 2026 Earnings Call

1Key Financial Results and Metrics

Cash Position: Ended Q2 2026 with approximately $1.01 billion in cash, cash equivalents, and investments, an increase of $198.5 million from the previous quarter.

Revenue: Recognized $238.9 million in license and collaboration revenue, primarily from a $240 million upfront payment from Astellas.

Expenses: R&D expenses totaled $135.3 million (up from $97.5 million YoY), influenced by a $48 million milestone payment to Sanofi. SG&A expenses were $30.2 million (up from $22.3 million YoY), driven by one-time advisory and legal costs.

Net Income: Reported net income of $80.1 million, a significant improvement from a net loss of $111.0 million in Q2 2025.

2Strategic Updates and Business Highlights

Hepatitis Delta Program: Completed enrollment in the ECLIPSE 2 trial and expects top-line data from ECLIPSE 1 in Q4 2026, followed by ECLIPSE 2 and 3 in Q1 2027. Presented promising data at the EASL Congress, indicating a potential best-in-class profile for the combination therapy of elebsiran and tobevibart.

Oncology Pipeline: Advancing the VIR-5500 T-cell engager in collaboration with Astellas. Multiple expansion cohorts are now enrolling, with plans to initiate Phase III registrational trials in 2027.

Manufacturing and Commercial Readiness: Completed drug substance process performance qualification for both lead therapies. Preparing for potential at-home administration of therapies to enhance patient convenience.

3Forward Guidance and Outlook

Cash Runway: Projected cash runway extends into the second half of 2028, supported by recent collaborations and funding.

Regulatory Submissions: Positioned to file comprehensive clinical data packages for hepatitis delta therapies following the completion of ECLIPSE studies.

Market Positioning: Anticipates that the approval of the first hepatitis delta therapy will enhance disease awareness and patient identification, potentially increasing market share.

4Bad News, Challenges, or Points of Concern

Management Turnover: Concerns regarding recent management changes and the ability to effectively manage distinct clinical programs were raised during the Q&A.

Competitive Landscape: The approval of bulevirtide may create competitive pressures; however, Vir believes its combination therapy offers a differentiated profile.

Regulatory Risks: Uncertainty remains regarding FDA acceptance of TND as a standalone endpoint for approval, although current trial designs reflect confidence in this approach.

5Notable Q&A Insights

ECLIPSE Trials: The company is exploring the potential for finite treatment in the ECLIPSE 2 and 3 trials, although this is not part of ECLIPSE 1.

Switch Data: ECLIPSE 2 data on patients switching from bulevirtide is expected to be valuable for future prescribing practices.

Human Factor Study: Ongoing studies aim to facilitate at-home administration of therapies, with a focus on co-packaging to enhance patient convenience.

Diagnosis Rates: Current U.S. HDV diagnosis rates are low (10-15%), but there is potential for improvement with increased awareness and testing protocols. Overall, Vir Biotechnology demonstrated strong financial performance and strategic progress in Q2 2026, while also facing challenges related to management stability and competitive pressures in the hepatitis delta market.